- MSdialog software chosen out of 45 entries by popular vote as winner for favorite product
- MSdialog designed to provide multiple sclerosis (MS) patients on Rebif (interferon beta-1a) and health care providers with injection history, treatment adherence information and health reports
- Award recognizes Merck Serono’s commitment to innovation and providing solutions to engage people with MS and their healthcare providers
Darmstadt, Germany, June 22, 2015 – Merck Serono, the biopharmaceutical business of Merck, today announced that MSdialog, the company’s digital-tracking software for people living with MS, has been chosen as the winner of this year’s Medical Design Excellence Awards (MDEA) Readers’ Choice Award, as well as honored as a finalist in the Rehabilitation and Assistive-Technology Products category for its compelling and innovative design. MDEA are the premier awards for the medical technology industry that honor the highest caliber medical devices on the market today.
Meeta Gulyani, Head of Global Strategy and Franchises, Merck Serono
Innovations are at the heart of Merck and its businesses like Merck Serono. In this biopharmaceutical business it is not only about innovations with new drugs but also with their applications by the patients. In this field Merck Serono also has a leading position which is more and more recognized and honored by the outside world for example with two Red Dot Design Awards announced last week and now with the Medical Design Excellence Awards (MDEA) Readers’ Choice Award.
“We are thrilled to be honored as the Readers Choice winner and an MDEA category finalist as it recognizes our commitment to innovation and to providing unique health care solutions to patients,” said Meeta Gulyani, Head of Global Strategy and Franchises at Merck Serono. “This award also acknowledges our position as a leading designer and developer in the medical device industry. To date, MSdialog has offered thousands of people with MS and their care team an efficient way to monitor their treatment adherence, track symptoms and improve the quality of conversations during visits with their HCPs. We are also delighted to recognize the contribution of our design partner, S3 Group, who played an important role in the design and delivery of MSdialog.”
Finalists will be featured in this month’s issue of Medical Device and Diagnostic Industry, a leading publication for the medical technology industry. The gold, silver and bronze winners in each category, in addition to Readers’ Choice and Best-in-Show Awards, were announced on June 9th at the official ceremony in New York City.
MSdialog is a multi-tenant cloud-based software system for the management of MS that captures and presents patient outcome data to enable better decision-making by patients and providers. The software system provides patients with reminders to take their Rebif® (interferon beta-1a) medication, synchronizes with the RebiSmart® 2 auto-injector, monitors patient’s adherence information to their treatment, and monitors clinical data. MSdialog also allows people with MS to engage in the management of their disease by asking them to complete periodic health report questionnaires based on short forms of published instruments and standard scales, such as the Multiple Sclerosis Quality of Life Inventory (MSQLI) and the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaires.
MSdialog is now available in 31 countries (not available in the United States).
About Medical Design Excellence Awards
Sponsored by MD+DI and organized by UBM Canon, MDEA is the premier awards program for the medical technology community. It recognizes the achievements of medical device manufacturers, their suppliers, and the many people behind the scenes—engineers, scientists, designers, and clinicians—who are responsible for the groundbreaking innovations that are changing the face of healthcare. MDEA-winning entries excel in the areas of product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery.
Rebif (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif in chronic progressive MS has not been established. Interferon ß is thought to help reduce inflammation. The exact mechanism is unknown. Rebif, which was approved in Europe in 1998 and in the US in 2002, is registered in more than 90 countries worldwide. Rebif has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area*. Rebif can be administrated with the RebiSmart electronic auto-injection device, or with the RebiDose single-use disposable pen, or the manual multidose injection pen RebiSlide. Rebif can also be administered with the autoinjector Rebiject II or by manual injection using ready-to-use pre-filled syringes. These injection devices are not available in all countries. In January 2012, the European commission approved the extension of the indication of Rebif in early multiple sclerosis. The extension of the indication of Rebif has not been submitted in the United States. Rebif should be used with caution in patients with a history of depression, liver disease and seizures. Most commonly reported side effects are flu-like symptoms, injection site disorders, elevation of liver enzymes and blood cell abnormalities. Patients, especially those with depression, seizure disorders, or liver problems, should discuss treatment with Rebif with their doctors.
About multiple sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million patients have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
About S3 Group
S3 Group is a leading designer of Connected Health Solutions. Headquartered in Dublin Ireland S3 Group specializes in delivering solutions that impact healthcare outcomes. This is the third time S3 Group has been honored as a supplier to an MDEA award winner. For more information please go to:
About Merck Serono
Merck Serono is the biopharmaceutical business of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono. Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit http://www.merckserono.com.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of around € 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
* The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.